I am in agreement here re. % chance of PMS gaining FDA approval given the strong results to date. It's important to keep in mind that this is an orphan drug for a rare disease with no existing treatment and therefore the hurdle for rejection is VERY high unless there's safety concern which is a non issue for NNZ 2561 as we know it.
Neuren Media and Analyst Coverage, page-721
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.85 |
Change
0.050(0.25%) |
Mkt cap ! $2.528B | |||
| Open | High | Low | Value | Volume |
| $19.95 | $20.04 | $19.59 | $815.9K | 41.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 63 | $19.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.88 | 99 | 4 |
View Market Depth
| Last trade - 10.24am 18/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.76 |
Change
0.050 ( 0.38 %) |
||||
| Open | High | Low | Volume | ||
| $19.99 | $20.04 | $19.60 | 12062 | ||
| Last updated 10.43am 18/06/2024 ? | |||||
| NEU (ASX) Chart |
